All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (liver ) PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
non squamous - mNSCLC - L1 - Wild Type (WT), atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96]
0.78 [0.68 ; 0.91 ] IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC WT), 2018 2 0% 1,375 moderate not evaluable progression or deaths (PFS)detailed results IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68]
IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74]
0.61 [0.54 ; 0.68 ] IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018 3 0% 1,655 moderate not evaluable DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
2.41 [1.27 ; 4.60 ] IMpower-130 (WT), 2019 1 0% 292 NA not evaluable objective responses (ORR)detailed results IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19]
IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55]
1.96 [1.60 ; 2.41 ] IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018 3 0% 1,637 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-03 07:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 176
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866
